These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1115 related articles for article (PubMed ID: 28404110)

  • 21. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
    Fuchs M; Monto A; Bräu N; Charafeddine M; Schmidt W; Kozal M; Naggie S; Cheung R; Schnell G; Yu Y; Richards K; Mullally V; Cohen DE; Toro D
    J Med Virol; 2020 Dec; 92(12):3459-3464. PubMed ID: 31829433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
    Poordad F; Sedghi S; Pockros PJ; Ravendhran N; Reindollar R; Lucey MR; Epstein M; Bank L; Bernstein D; Trinh R; Krishnan P; Polepally AR; Unnebrink K; Martinez M; Nelson DR
    J Viral Hepat; 2019 Aug; 26(8):1027-1030. PubMed ID: 30980576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
    Said M; Omar H; Soliman Z; Saad Y; Dabes H; Hamed S; ElSaeed K; ElShazly Y; ElSerafy M
    Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):89-93. PubMed ID: 30791838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
    Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
    J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
    Cheng EY; Saab S; Holt CD; Busuttil RW
    Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
    Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
    Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
    Chayama K; Notsumata K; Kurosaki M; Sato K; Rodrigues L; Setze C; Badri P; Pilot-Matias T; Vilchez RA; Kumada H
    Hepatology; 2015 May; 61(5):1523-32. PubMed ID: 25644279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
    J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
    J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
    Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
    Shiffman ML; Rustgi V; Bennett M; Forns X; Asselah T; Planas Vila R; Liu L; Pedrosa M; Moller J; Reau N
    Am J Gastroenterol; 2016 Jun; 111(6):845-51. PubMed ID: 27045929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
    Yu ML; Chen YL; Huang CF; Lin KH; Yeh ML; Huang CI; Hsieh MH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL
    J Formos Med Assoc; 2018 Jun; 117(6):518-526. PubMed ID: 28662883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
    Trifan A; Stanciu C; Gheorghe L; Iacob S; Curescu M; Cijevschi Prelipcean C; Stefanescu G; Girleanu I; Chiriac S; Mihai C; Brisc C; Goldis A; Sporea I; Miftode E; Bataga S; Rogoveanu I; Preda C; Caruntu FA; Singeap AM
    Medicine (Baltimore); 2017 Dec; 96(50):e9271. PubMed ID: 29390377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
    Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
    J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
    Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
    Ferenci P; Bernstein D; Lalezari J; Cohen D; Luo Y; Cooper C; Tam E; Marinho RT; Tsai N; Nyberg A; Box TD; Younes Z; Enayati P; Green S; Baruch Y; Bhandari BR; Caruntu FA; Sepe T; Chulanov V; Janczewska E; Rizzardini G; Gervain J; Planas R; Moreno C; Hassanein T; Xie W; King M; Podsadecki T; Reddy KR; ;
    N Engl J Med; 2014 May; 370(21):1983-92. PubMed ID: 24795200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
    Kowdley KV; Lawitz E; Poordad F; Cohen DE; Nelson DR; Zeuzem S; Everson GT; Kwo P; Foster GR; Sulkowski MS; Xie W; Pilot-Matias T; Liossis G; Larsen L; Khatri A; Podsadecki T; Bernstein B
    N Engl J Med; 2014 Jan; 370(3):222-32. PubMed ID: 24428468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
    Zeuzem S; Jacobson IM; Baykal T; Marinho RT; Poordad F; Bourlière M; Sulkowski MS; Wedemeyer H; Tam E; Desmond P; Jensen DM; Di Bisceglie AM; Varunok P; Hassanein T; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
    N Engl J Med; 2014 Apr; 370(17):1604-14. PubMed ID: 24720679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.